Literature DB >> 17308095

Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells.

Kerstin Jungert1, Anita Buck, Götz von Wichert, Guido Adler, Alexander König, Malte Buchholz, Thomas M Gress, Volker Ellenrieder.   

Abstract

Transition from a sessile epithelial phenotype to a migrating mesenchymal phenotype is a crucial step in transforming growth factor-beta (TGF-beta)-induced pancreatic cancer cell migration and invasion. These profound morphologic and functional alterations are associated with characteristic changes in TGF-beta-regulated gene expression, defined by rapid repression of epithelial markers and a strong and sustained transcriptional induction of mesenchymal markers such as the intermediate filament vimentin. In this study, we have analyzed the role of the transcription factor Sp1 in TGF-beta-induced and Smad-mediated gene regulation during epithelial to mesenchymal transition (EMT) and migration of pancreatic cancer cells. Here, we show that Sp1 is required for TGF-beta-induced EMT, and that this function is especially mediated through transcriptional induction of vimentin. Our results emphasize the functional relevance of vimentin in TGF-beta-induced EMT because prevention of its induction strongly reduces cell migration. Altogether, this study helps to better understand the role of Sp1 in TGF-beta-induced progression of pancreatic cancer. It suggests that Sp1, via transcriptional induction of vimentin, cooperates with activated Smad complexes in mesenchymal transition and migration of pancreatic cancer cells upon TGF-beta stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308095     DOI: 10.1158/0008-5472.CAN-06-1670

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells.

Authors:  Kazuo Asanoma; Ge Liu; Takako Yamane; Yoko Miyanari; Tomoka Takao; Hiroshi Yagi; Tatsuhiro Ohgami; Akimasa Ichinoe; Kenzo Sonoda; Norio Wake; Kiyoko Kato
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

2.  Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.

Authors:  Yong Gao; Zhiliang Jia; Xiangyu Kong; Qiang Li; David Z Chang; Daoyan Wei; Xiangdong Le; Huang Suyun; Shengdong Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2011-06-14       Impact factor: 12.701

3.  Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma.

Authors:  Yasunori Sato; Kenichi Harada; Keita Itatsu; Hiroko Ikeda; Yuko Kakuda; Syuji Shimomura; Xiang Shan Ren; Norihide Yoneda; Motoko Sasaki; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

4.  β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition.

Authors:  Jishun Lu; Tomoya Isaji; Sanghun Im; Tomohiko Fukuda; Noritaka Hashii; Daisuke Takakura; Nana Kawasaki; Jianguo Gu
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

5.  Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer.

Authors:  Han-Qing Wu; Bo Wang; Shi-Kai Zhu; Yuan Tian; Jing-Hui Zhang; He-Shui Wu
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

6.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.

Authors:  Kelly J Gordon; Kellye C Kirkbride; Tam How; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-12-04       Impact factor: 4.944

8.  Gene expression profiles associated with advanced pancreatic cancer.

Authors:  Domenico Campagna; Leslie Cope; Sindhu S Lakkur; Clark Henderson; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy.

Authors:  Christine A Iacobuzio-Donahue
Journal:  J Gastrointest Surg       Date:  2012-06-29       Impact factor: 3.452

10.  An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules.

Authors:  Huaxia Qin; Michael W Y Chan; Sandya Liyanarachchi; Curtis Balch; Dustin Potter; Irene J Souriraj; Alfred S L Cheng; Francisco J Agosto-Perez; Elena V Nikonova; Pearlly S Yan; Huey-Jen Lin; Kenneth P Nephew; Joel H Saltz; Louise C Showe; Tim H M Huang; Ramana V Davuluri
Journal:  BMC Syst Biol       Date:  2009-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.